References:
1. Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, et
al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020.
Rhinology. 2020;58(Suppl S29):1-464.
2. Hellings PW, Akdis CA, Bachert C, Bousquet J, Pugin B, Adriaensen G,
et al. EUFOREA Rhinology Research Forum 2016: report of the
brainstorming sessions on needs and priorities in rhinitis and
rhinosinusitis. Rhinology. 2017;55(3):202-10.
3. Orlandi RR, Kingdom TT, Smith TL, Bleier B, DeConde A, Luong AU, et
al. International consensus statement on allergy and rhinology:
rhinosinusitis 2021. Int Forum Allergy Rhinol. 2021;11(3):213-739.
4. Bachert C, Hellings PW, Lund VJ, Fokkens WJ, Hopkins C, Mayer B, et
al. Mepolizumab improves quality of life and reduces activity
impairments in patients with CRSwNP. Rhinology. 2022;60(6):474-8.
5. Bachert C, Zhang N, Cavaliere C, Weiping W, Gevaert E, Krysko O.
Biologics for chronic rhinosinusitis with nasal polyps. J Allergy Clin
Immunol. 2020;145(3):725-39.
6. Hellings PW, Fokkens WJ, Orlandi R, Adriaensen GF, Alobid I, Baroody
FM, et al. The EUFOREA pocket guide for chronic rhinosinusitis.
Rhinology. 2023;61(1):85-9.
7. Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, et al.
EUFOREA expert board meeting on uncontrolled severe chronic
rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and
management. J Allergy Clin Immunol. 2021;147(1):29-36.
8. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et
al. EUFOREA consensus on biologics for CRSwNP with or without asthma.
Allergy. 2019;74(12):2312-9.
9. Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, et
al. EPOS/EUFOREA update on indication and evaluation of Biologics in
Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology.
2023;61(3):194-202.
10. Head K, Chong LY, Hopkins C, Philpott C, Burton MJ, Schilder AG.
Short-course oral steroids alone for chronic rhinosinusitis. Cochrane
Database Syst Rev. 2016;4(4):Cd011991.
11. Hox V, Lourijsen E, Jordens A, Aasbjerg K, Agache I, Alobid I, et
al. Benefits and harm of systemic steroids for short- and long-term use
in rhinitis and rhinosinusitis: an EAACI position paper. Clin Transl
Allergy. 2020;10:1.
12. Deng J, Wang Z, Xu Z, Lai Y, Zheng R, Gao W, et al. Blood
eosinophils to direct oral corticosteroid treatment for patients with
nasal polyps â\euro” an open label, non-inferiority, randomized
control trial. Rhinology. 2023;61(4):328-37.
13. GINA Main Report 2023 2023 [
14. Van Zele T, Gevaert P, Holtappels G, Beule A, Wormald PJ, Mayr S, et
al. Oral steroids and doxycycline: two different approaches to treat
nasal polyps. J Allergy Clin Immunol. 2010;125(5):1069-76.e4.
15. De Corso E, Pipolo C, Cantone E, Ottaviano G, Gallo S, Canevari FRM,
et al. Survey on Use of Local and Systemic Corticosteroids in the
Management of Chronic Rhinosinusitis with Nasal Polyps: Identification
of Unmet Clinical Needs. J Pers Med. 2022;12(6).
16. Hopkins C, Surda P, Walker A, Wolf A, Speth MM, Jacques T, et al.
EPOS 4 Patients. Rhinology. 2021.
17. Bhattacharyya N, Villeneuve S, Joish VN, Amand C, Mannent L, Amin N,
et al. Cost burden and resource utilization in patients with chronic
rhinosinusitis and nasal polyps. Laryngoscope. 2019;129(9):1969-75.
18. De Corso E, Settimi S, Montuori C, Cantiani A, Corbò M, Di Bella GA,
et al. How to manage recurrences after surgery in CRSwNP patients in the
biologic era: a narrative review. Acta Otorhinolaryngol Ital.
2023;43(Suppl. 1):S3-s13.
19. Rudmik L, Soler ZM, Hopkins C, Schlosser RJ, Peters A, White AA, et
al. Defining appropriateness criteria for endoscopic sinus surgery
during management of uncomplicated adult chronic rhinosinusitis: a
RAND/UCLA appropriateness study. Rhinology. 2016;54(2):117-28.
20. De Prins L, Raap U, Mueller T, Schmid-Grendelmeier P, Haase CH,
Backer V, et al. White Paper on European Patient Needs and Suggestions
on Chronic Type 2 Inflammation of Airways and Skin by EUFOREA. Front
Allergy. 2022;3:889221.
21. Loftus CA, Soler ZM, Koochakzadeh S, Desiato VM, Yoo F, Nguyen SA,
et al. Revision surgery rates in chronic rhinosinusitis with nasal
polyps: meta-analysis of risk factors. Int Forum Allergy Rhinol.
2020;10(2):199-207.
22. Hox V, Delrue S, Scheers H, Adams E, Keirsbilck S, Jorissen M, et
al. Negative impact of occupational exposure on surgical outcome in
patients with rhinosinusitis. Allergy. 2012;67(4):560-5.
23. Kim DH, Han JS, Kim GJ, Basurrah MA, Hwang SH. Clinical predictors
of polyps recurring in patients with chronic rhinosinusitis and nasal
polyps: a systematic review and meta-analysis. Rhinology. 2023.
24. Lourijsen ES, Reitsma S, Vleming M, Hannink G, Adriaensen G, Cornet
ME, et al. Endoscopic sinus surgery with medical therapy versus medical
therapy for chronic rhinosinusitis with nasal polyps: a multicentre,
randomised, controlled trial. Lancet Respir Med. 2022;10(4):337-46.
25. Vlaminck S, Acke F, Prokopakis E, Speleman K, Kawauchi H, van Cutsem
JC, et al. Surgery in Nasal Polyp Patients: Outcome After a Minimum
Observation of 10 Years. Am J Rhinol Allergy. 2021;35(4):449-57.
26. Cao Y, Hong H, Sun Y, Lai Y, Xu R, Shi J, et al. The effects of
endoscopic sinus surgery on pulmonary function in chronic rhinosinusitis
patients with asthma: a systematic review and meta-analysis. Eur Arch
Otorhinolaryngol. 2019;276(5):1405-11.
27. Vashishta R, Soler ZM, Nguyen SA, Schlosser RJ. A systematic review
and meta-analysis of asthma outcomes following endoscopic sinus surgery
for chronic rhinosinusitis. Int Forum Allergy Rhinol. 2013;3(10):788-94.
28. Vennik J, Eyles C, Thomas M, Hopkins C, Little P, Blackshaw H, et
al. Chronic rhinosinusitis: a qualitative study of patient views and
experiences of current management in primary and secondary care. BMJ
Open. 2019;9(4):e022644.
29. Hamada K, Oishi K, Chikumoto A, Murakawa K, Ohteru Y, Matsuda K, et
al. Impact of sinus surgery on type 2 airway and systemic inflammation
in asthma. J Asthma. 2021;58(6):750-8.
30. Arancibia C, Langdon C, Mullol J, Alobid I. Twelve-year long-term
postoperative outcomes in patients with chronic rhinosinusitis with
nasal polyps. Rhinology. 2022;60(4):261-9.
31. van der Lans RJL, Hopkins C, Senior BA, Lund VJ, Reitsma S.
Biologicals and Endoscopic Sinus Surgery for Severe Uncontrolled Chronic
Rhinosinusitis With Nasal Polyps: An Economic Perspective. J Allergy
Clin Immunol Pract. 2022;10(6):1454-61.
32. van der Veen J, Seys SF, Timmermans M, Levie P, Jorissen M, Fokkens
WJ, et al. Real-life study showing uncontrolled rhinosinusitis after
sinus surgery in a tertiary referral centre. Allergy. 2017;72(2):282-90.
33. Phillips KM, Singerman KW, Sedaghat AR. Individual symptom visual
analogue scale severity scores for determining EPOS guideline-based
chronic rhinosinusitis disease control. Rhinology. 2022;60(3):229-35.
34. Viskens AS, Wils T, Van Bulck P, Cools L, Vanderveken O, Hellings
PW. Multiple reasons underlaying uncontrolled disease in the majority of
chronic rhinosinusitis patients. Front Allergy. 2022;3:1048385.
35. Fokkens WJ, Pugin B, Bachert C, Bousquet J, Joos G, Louis R, et al.
Rhinology Future Debates 2017 by EUFOREA: Novel treatments and surgical
solutions in rhinology. Clin Otolaryngol. 2018;43(6):1429-38.
36. Bewick J, Egro FM, Masterson L, Javer AR, Philpott CM. Anatomic
findings in revision endoscopic sinus surgery: Case series and review of
contributory factors. Allergy Rhinol (Providence). 2016;7(3):151-7.
37. Krings JG, Kallogjeri D, Wineland A, Nepple KG, Piccirillo JF, Getz
AE. Complications of primary and revision functional endoscopic sinus
surgery for chronic rhinosinusitis. Laryngoscope. 2014;124(4):838-45.
38. Hellings PW. From prevention to optimal treatment in chronic
rhinosinusitis. Rhinology. 2018;56(4):305-6.
39. Lee SE, Hopkins C, Mullol J, Msihid J, Guillemin I, Amin N, et al.
Dupilumab improves health related quality of life: Results from the
phase 3 SINUS studies. Allergy. 2022;77(7):2211-21.
40. Mullol J, Laidlaw TM, Bachert C, Mannent LP, Canonica GW, Han JK, et
al. Efficacy and safety of dupilumab in patients with uncontrolled
severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis
of NSAID-ERD: Results from two randomized placebo-controlled phase 3
trials. Allergy. 2022;77(4):1231-44.
41. Fokkens WJ, Mullol J, Kennedy D, Philpott C, Seccia V, Kern RC, et
al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE):
In-depth sinus surgery analysis. Allergy. 2023;78(3):812-21.
42. Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, et al.
Evaluating treatment response to mepolizumab in patients with severe
CRSwNP. Rhinology. 2023;61(2):108-17.
43. Roland LT, Wise SK, Wang H, Mehta C, DelGaudio JM, Levy JM.
Influence of omalizumab on treatment costs for chronic rhinosinusitis
with nasal polyps and asthma: an insurance claims analysis. Int Forum
Allergy Rhinol. 2022;12(3):310-2.
44. Striz I, Golebski K, Strizova Z, Loukides S, Bakakos P, Hanania NA,
et al. New insights into the pathophysiology and therapeutic targets of
asthma and comorbid chronic rhinosinusitis with or without nasal
polyposis. Clin Sci (Lond). 2023;137(9):727-53.
45. Kariyawasam HH, Chandrasekharan DP, Jacques T, Stokes P, Dziadzio M,
Gane SB, et al. Biologic treatment for severe chronic rhinosinusitis
with nasal polyps: a systematic review and meta-analysis. Rhinology.
2023;61(2):98-107.
46. De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F,
Ottaviano G, et al. Dupilumab in the treatment of severe uncontrolled
chronic rhinosinusitis with nasal polyps (CRSwNP): A multicentric
observational Phase IV real-life study (DUPIREAL). Allergy.
2023;78(10):2669-83.
47. Oykhman P, Paramo FA, Bousquet J, Kennedy DW, Brignardello-Petersen
R, Chu DK. Comparative efficacy and safety of monoclonal antibodies and
aspirin desensitization for chronic rhinosinusitis with nasal polyposis:
A systematic review and network meta-analysis. J Allergy Clin Immunol.
2022;149(4):1286-95.
48. Haxel BR, Hummel T, Fruth K, Lorenz K, Gunder N, Nahrath P, et al.
Real-world-effectiveness of biological treatment for severe chronic
rhinosinusitis with nasal polyps. Rhinology. 2022;60(6):435-43.
49. van der Lans RJL, Otten JJ, Adriaensen G, Hoven DR, Benoist LB,
Fokkens WJ, et al. Two-year results of tapered dupilumab for CRSwNP
demonstrates enduring efficacy established in the first 6 months.
Allergy. 2023.
50. Hellings PW, Verhoeven E, Fokkens WJ. State-of-the-art overview on
biological treatment for CRSwNP. Rhinology. 2021;59(2):151-63.
51. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, et al.
Efficacy and safety of dupilumab in patients with severe chronic
rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP
SINUS-52): results from two multicentre, randomised, double-blind,
placebo-controlled, parallel-group phase 3 trials. Lancet.
2019;394(10209):1638-50.
52. Lans R, Fokkens WJ, Adriaensen G, Hoven DR, Drubbel JJ, Reitsma S.
Real-life observational cohort verifies high efficacy of dupilumab for
chronic rhinosinusitis with nasal polyps. Allergy. 2022;77(2):670-4.
53. Xu X, Reitsma S, Wang Y, Fokkens WJ. Updates in biologic therapy for
chronic rhinosinusitis with nasal polyps and NSAID-exacerbated
respiratory disease. Allergy. 2022;77(12):3593-605.
54. Agache I, Song Y, Alonso-Coello P, Vogel Y, Rocha C, Solà I, et al.
Efficacy and safety of treatment with biologicals for severe chronic
rhinosinusitis with nasal polyps: A systematic review for the EAACI
guidelines. Allergy. 2021;76(8):2337-53.
55. Desrosiers M, Mannent LP, Amin N, Canonica GW, Hellings PW, Gevaert
P, et al. Dupilumab reduces systemic corticosteroid use and sinonasal
surgery rate in CRSwNP. Rhinology. 2021;59(3):301-11.
56. Shakuntulla F, Chiarella SE. Safety of Biologics for Atopic Diseases
During Pregnancy. J Allergy Clin Immunol Pract. 2022;10(12):3149-55.
57. Pfaller B, José Yepes-Nuñez J, Agache I, Akdis CA, Alsalamah M,
Bavbek S, et al. Biologicals in atopic disease in pregnancy: An EAACI
position paper. Allergy. 2021;76(1):71-89.
58. Namazy JA, Blais L, Andrews EB, Scheuerle AE, Cabana MD, Thorp JM,
et al. Pregnancy outcomes in the omalizumab pregnancy registry and a
disease-matched comparator cohort. J Allergy Clin Immunol.
2020;145(2):528-36.e1.
59. Ryser FS, Yalamanoglu A, Valaperti A, Brühlmann C, Mauthe T, Traidl
S, et al. Dupilumab-induced eosinophilia in patients with diffuse type 2
chronic rhinosinusitis. Allergy. 2023;78(10):2712-23.
60. Soyka MB, Ryser FS, Brühlmann C, Fehr D, Dülgeroglu J,
Schmid-Grendelmeier P, et al. Predicting dupilumab treatment outcome in
patients with primary diffuse type 2 chronic rhinosinusitis. Allergy.
2023;78(4):1036-46.
61. Lommatzsch M, Stoll P, Winkler J, Zeise-Wehry D, Tronnier M, Weber
MA, et al. Eosinophilic pleural effusion and stroke with cutaneous
vasculitis: Two cases of dupilumab-induced hypereosinophilia. Allergy.
2021;76(9):2920-3.
62. Lifar P, Montastruc F, Reber LL, Magnaval JF, Guilleminault L.
Parasitic Infections and Biological Therapies Targeting Type 2
Inflammation: A VigiBase Study. Am J Respir Crit Care Med.
2023;207(9):1253-5.
63. Rothenberg ME, Roufosse F, Faguer S, Gleich GJ, Steinfeld J, Yancey
SW, et al. Mepolizumab Reduces Hypereosinophilic Syndrome Flares
Irrespective of Blood Eosinophil Count and Interleukin-5. J Allergy Clin
Immunol Pract. 2022;10(9):2367-74.e3.
64. Hopkins C. Ethical dilemmas associated with the introduction of
biologic treatments in chronic rhinosinusitis with nasal polyps.
Rhinology. 2022;60(3):162-8.
65. van der Lans RJL, Fokkens WJ, Reitsma S. Therapeutic Options for
Chronic Rhinosinusitis in N-ERD Patients. Front Allergy. 2021;2:734000.
66. Yong M, Wu YQ, Howlett J, Ballreich J, Walgama E, Thamboo A.
Cost-effectiveness analysis comparing dupilumab and aspirin
desensitization therapy for chronic rhinosinusitis with nasal polyposis
in aspirin-exacerbated respiratory disease. Int Forum Allergy Rhinol.
2021;11(12):1626-36.
67. Van Broeck D, Steelant B, Scadding G, Hellings PW. Monoclonal
antibody or aspirin desensitization in NSAID-exacerbated respiratory
disease (N-ERD)? Front Allergy. 2023;4:1080951.
68. Pendolino AL, Scadding GK, Scarpa B, Andrews PJ. A retrospective
study on long-term efficacy of intranasal lysine-aspirin in controlling
NSAID-exacerbated respiratory disease. Eur Arch Otorhinolaryngol.
2022;279(5):2473-84.
69. Stevens WW, Jerschow E, Baptist AP, Borish L, Bosso JV, Buchheit KM,
et al. The role of aspirin desensitization followed by oral aspirin
therapy in managing patients with aspirin-exacerbated respiratory
disease: A Work Group Report from the Rhinitis, Rhinosinusitis and
Ocular Allergy Committee of the American Academy of Allergy, Asthma &
Immunology. J Allergy Clin Immunol. 2021;147(3):827-44.
70. Aydin Ö, Atmiş E, Anadolu Y, Yorulmaz İ, Çelik GE. Aspirin
desensitization following endoscopic sinus surgery is effective
in patients with nonsteroidal antiinflammatory drug exacerbated
respiratory disease. J Asthma. 2023;60(6):1131-40.